

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT THE STRATEGIC COLLABORATION WITH GUANGDONG HICICARE SCIENCE CO., LTD.

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”, “**we**” or “**our**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that, in order to enhance the Company’s offerings of the pan-vascular interventional access products, the Company has entered into a strategic collaboration agreement with Guangdong Hicicare Science Co., Ltd. (廣東海思卡爾醫療科技有限公司) (“**Guangdong Hicicare**”), a China-based innovative medical device company and an independent third party of the Company, to promote and market the peripheral-vascular interventional and neurovascular interventional guidewire products in China. The Company’s peripheral-vascular interventional business unit, Zhejiang Zylox Medical, will gradually launch the “Zylox-Hicicare Guidewire Family” products to address various clinical needs which range from the imaging diagnosis to opening and treatment of diseases, including stenosis, moderate to severe calcification, and complete occlusion lesions. The Company’s neurovascular interventional business unit, Zhuhai Tonbridge Medical, developed independently and worked with Guangdong Hicicare to launch the Beidou series micro guide wires, which can meet the different clinical treatment needs of ischemic and hemorrhagic stroke.

Guidewires are one of the most fundamental tools in the vascular interventional procedures. Excellent performance of the guidewires can provide a safer and more efficient surgical experience for interventional procedures and reduce the occurrence of surgical complications. According to industry estimates, the number of neuro-interventional procedures in China is estimated to increase from 159.6 thousand in 2019 to 1,781.0 thousand in 2030, at a compound annual growth rate (“**CAGR**”) of 24.5% from 2019 to

2030, and the number of peripheral artery intervention procedures in China is estimated to increase from 112.2 thousand in 2019 to reach 600.1 thousand in 2030 at a CAGR of 16.5% from 2019 to 2030. Given the high technological barriers and device usage habits, the interventional guidewire market in China is still dominated by multinational companies. The increase penetration of vascular interventional procedures is expected to boost the demand for guidewires, and we believe there is a huge potential for domestic manufacturers to compete for market share.

Collaboration with Guangdong Hicicare represents our diversified strategy to expand our product offering and accelerate toward our goal to provide comprehensive treatment solutions to patients and physicians. The Company believes that the strategic collaborations with high-quality medical companies in China and globally will be one of its important growth drivers in the future.

By order of the board of directors
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, April 20, 2023

As of the date of this announcement, the Board of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.